HealthyDirect · GrowthFit for a long SIP
Mirae Asset Healthcare Fund
Mirae Asset Mutual FundEquity Schemes - Thematic Fund8.3 years
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India.
- NAV
- 51.111
- 29 Oct 2026
- 1Y
- +16.9%
- Trailing CAGR
- AUM
- ₹3,494.44 Cr
- 30 Sept 2026
- Volatility
- Medium
- 15.7% annualized
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 70% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Buy checklist
History depth
Pass
8.3 years of path to read.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.62% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -20.0%. Ask whether you can hold through a similar fall.
Vs category
Pass
70% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Watch
Tanmay Mehta · 1.6 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 58.4% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 20%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+16.9%
- 3Y+23.5%
- 5Y+16.4%
- 10Yn/a
- SI+21.6%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+22.3%
- 3Y+16.8%
- 5Y+19.8%
- 10Yn/a
- Since inception
- +21.6%
- Calendar-day CAGR
- Excess 1Y
- +21.4%
- Category median, same plan and option
- 3Y win rate
- +70%
- Windows beating the median
- 3Y percentile
- 90
- Vs comparable share classes
- SIP 3Y XIRR
- +16.8%
- Simulated monthly SIP
- Worst rolling 3Y
- +14.2%
- 1312 daily-ending windows
- Median rolling 3Y
- +23.2%
- Calendar-day CAGR
- Positive rolling 5Y
- +100%
- 820 daily-ending windows
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -20.0%
- Worst peak-to-trough
- Current
- -3.8%
- Below last peak
- Current spell
- 36 days
- Days below latest peak
- Time below peak
- +87%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 11 days
- 110 recovered episodes
- Longest recovery
- 389 days
- Trough to prior peak
20 Feb 2020 – 8 Apr 2020
Trough 23 Mar 2020 · recovered in 16 days
-20.0%
3 Jan 2022 – 11 Jul 2023
Trough 17 Jun 2022 · recovered in 389 days
-18.5%
2 Jan 2025 – 17 Jul 2025
Trough 28 Feb 2025 · recovered in 139 days
-15.9%
7 Sept 2018 – 3 Jan 2020
Trough 7 Oct 2019 · recovered in 88 days
-12.1%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
90
Vs category
100
Consistency
66
Risk-adjusted
74
Drawdown
50
Mean
76
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 70% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 30 holdings · top 10 are 58.4%.
- Top 5
- 37.9%
- Top 10
- 58.4%
- Largest holding
- 10.2%
- Effective holdings
- 20.0
Sun Pharmaceutical Industries Ltd
Healthcare
10.2%
Divi's Laboratories Ltd
Healthcare
9.8%
Torrent Pharmaceuticals Ltd
Healthcare
6.8%
Apollo Hospitals Enterprise Ltd
Healthcare
5.6%
Laurus Labs Ltd
Healthcare
5.5%
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
WhiteOak Capital Special Opportunities Fund
WhiteOak Capital Mutual Fund
- 1Y
- +7.2%
- 3Y
- n/a
- Vol
- 14.7%
- Max DD
- -17.0%
- Sharpe
- 0.67
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
Caveat: Higher TER · Lower trailing returns
BANDHAN INNOVATION FUND
Bandhan Mutual Fund
- 1Y
- +10.7%
- 3Y
- n/a
- Vol
- 17.0%
- Max DD
- -19.7%
- Sharpe
- 0.76
- 3Y win
- n/a
- Shallower drawdown
- Higher win rate vs category
Caveat: Higher volatility · Higher TER · Lower trailing returns
HSBC Financial Services fund
HSBC Mutual Fund
- 1Y
- -0.9%
- 3Y
- n/a
- Vol
- 17.0%
- Max DD
- -14.8%
- Sharpe
- 0.36
- 3Y win
- n/a
- Shallower drawdown
- Higher win rate vs category
Caveat: Higher volatility · Higher TER · Lower trailing returns
Mirae Asset Great Consumer Fund
Mirae Asset Mutual Fund
- 1Y
- -8.6%
- 3Y
- +10.1%
- Vol
- 14.5%
- Max DD
- -35.5%
- Sharpe
- 0.72
- 3Y win
- +71%
- Lower volatility
- Higher win rate vs category
Caveat: Deeper drawdown · Higher TER · Lower trailing returns
Nippon India Taiwan Equity Fund
Nippon India Mutual Fund
- 1Y
- +85.1%
- 3Y
- +57.9%
- Vol
- 33.9%
- Max DD
- -44.8%
- Sharpe
- 0.80
- 3Y win
- +72%
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown · Higher TER